Cellectar Biosciences announced today a multi-year supply agreement with Ionetix Corporation, a full-service radioisotope manufacturer.

According to a release, Ionetix will provide Cellectar with a clinical and commercial-scale supply of cGMP-grade Ac-225 and At-211 to support its drug development programs through clinical trials and into potential commercial launches of targeted alpha therapy candidates.

“As we prepare for the future expansion of Cellectar’s radiotherapeutic pipeline beyond our beta and Auger emitter clinical programs and work to advance CLR-225 into clinical trials as a potential treatment for challenging solid tumor cancers such as pancreatic cancer, establishing a dependable and fully scalable supply of high-quality alpha-emitting isotopes is essential for the development of our targeted PRC pipeline,” Cellectar Biosciences Chief Operating Officer Jarrod Longcor said in a statement. “This collaboration with Ionetix ensures sufficient supply of these isotopes moving forward.”

The financial terms of the agreement were not disclosed.